Efficacy and safety of intracoronary prourokinase during percutaneous coronary intervention in treating ST-segment elevation myocardial infarction patients: a randomized, controlled study

Table 6 MACE during 3-month follow up

Items	Intracoronary prourokinase group (N = 25)	Control groups (N = 25)	P value
Total MACE, No. (%)	3 (12.0)	7 (28.0)	0.157
Cardiac death, No. (%)	0 (0.0)	0 (0.0)	–
Stent thrombosis, No. (%)	0 (0.0)	1 (4.0)	1.000
TVR, No. (%)	0 (0.0)	0 (0.0)	–
Heart failure, No. (%)	2 (8.0)	4 (16.0)	0.667
Malignant arrhythmia, No. (%)	1 (4.0)	2 (8.0)	0.552
Stroke, No. (%)	0 (0.0)	0 (0.0)	–

Differences between two groups were determined by Fisher’s exact test. MACE major adverse cardiac events, TVR target vessel revascularization

ISSN: 1471-2261